TFs of AP-1, regulating TNFα, IL-6 and SELE are implicated as oncogenes or tumor suppressors in many cancers [46–48] with drug development programs targeting cJun, JunB, JunD, cFos, FosB, Fra1 and Fra2 [49]. Here, FOSL2 is linked to neoplasm.